THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY

HOME
VYEPTI
RESOURCES
REPORT AN ADVERSE EVENT
PRESCRIBING INFORMATION

VYEPTI® (EPTINEZUMAB) IS INDICATED FOR THE PROPHYLAXIS OF MIGRAINE IN ADULTS WHO HAVE AT LEAST 4 MIGRAINE DAYS PER MONTH¹
PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING CAN BE ACCESSED VIA THE TABS AT THE TOP OF THIS PAGE

SIGN UP STAY IN TOUCH

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Lundbeck Limited,
on: 01908 638972 or Email: SafetyLuUnitedKingdom@lundbeck.com

Reference